Faculty Profile


Edward Ball, M.D.
Dr. Ball

Edward Ball, M.D.

Professor of Medicine
Chief, Division of Bone Marrow Transplantation

Office Address:

Division of Bone Marrow Transplantation

University of California

Moores UCSD Cancer Center

3855 Health Sciences Drive, MC-0960

La Jolla, CA  92093


Office: (858) 822-6842
FAX: (858) 822-6844

Education and Training

BS Biochemistry, University of Maryland 1968-1972
MD Case Western Reserve University 1972-1976
Resident Hartford Hospital 1976-1979
Fellow Hematology & Oncolog), University Hospitals of Cleveland


Fellow Hematology & Oncology, Dartmouth- Hitchcock Medical Center 1982-1983


Research Interests

Dr. Ball’s research focuses on the development of monoclonal antibody (mAb)-targeted immunotherapy and its translation to the treatment of patients with malignancy. His lab produced mAbs to myeloid-associated antigens expressed on myeloid leukemia cells. These antibodies have been used clinically for the diagnosis and treatment of acute myeloid leukemia (AML).He has conducted multi-center clinical trials using antibody-mediated purging using the AML cells from the marrow of patients with leukemia prior to transplantation, after high dose chemotherapy. He has also developed in vivo therapeutics using an anti-CD15 mAb and a bispecific antibody. This bispecific antibody (251xH22) mediates antibody–directed cellular cytotoxicity(ADCC) of AML cells mediated by normal leukocyte cells including natural killer cells, monocytes and granulocytes. They determined that there are direct signals transduced by binding of the anti-CD33 monoclonal antibody that lead to death of AML cells mediated in part by the protein kinase Syk.  This led to an investigator-initiated multi-center Phase I/II clinical trial combining 5-azacytidine (that increases Syk expression) and the anti-CD33 monoclonal antibody Mylotarg.  His laboratory has also been working the generation of cytotoxic T cells in vitro in a novel culture system.  Based on this pre-clinical work, they developed a clinical trial wherein patients with AML undergoing autologous stem cell transplantation are administered autologous cytotoxic T cells following the transplant with the goal of reducing the relapse rate.  Dr. Ball is principal investigator on numerous clinical trials active at UCSD Medical Center ranging from Phase I investigator-initiated to Phase III trials.  He has been a recipient of a NCI and NHLBI-sponsored UO1 grant from the NIH.  He recently completed a study of a novel treatment of relapse following allogeneic stem cell transplantation.  The infusion of a monoclonal antibody directed to the cytotoxic T lymphocyte antigen-4 (CTLA-4) was tested in series of patients with relapse for safety and efficacy. The study demonstrated the safety of this approach and some promising signs of efficacy. Dr. Ball has been the elected Secretary of the American Society of Blood and Marrow Transplantation and a member of the steering committee of the BMT Clinical Trials Network. 


Zhong RK, Lane TA, Ball ED. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.  Exp Hematol, 36(4):486-94, 2008.

Bashey, A., Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Streicher H, Lowy I, Solomon SR, Morris LE, Holland K, Mason J. Soiffer R, Ball ED.:  CTLA4 Blockade with Ipilimumab to Treat Relapse of Malignancy after Allogeneic Hematopoietic Cell Transplantation. Blood 113(7):1581-8, 2009.

Trivedi M, Martinez S, Corringham S, Ball ED, Medley K. Optimal use of G-CSF administration after hematopoietic stem cell transplantation.  Bone Marrow Transplant, 43(12):895-908, 2009.

Jung A, Holman P, Castro E, Carrier E, Lane T, Nelson C, Pu M, Messer K, Corringham S, Ball ED.  Autologous Hematopoietic Stem Cell Transplantation as an Intensive Consolidation Therapy for Adult Patients in Remission from Acute Myeloid Leukemia. Biol. Blood and Marrow Transplant. 15(10):1306-13, 2009

Messer K, Natarajan L, Ball ED, Lane T. Dose-establishment designs for phase I/II cancer immunotherapy trials. Statistics in Medicine. 29: 712-720, 2010.

Ball ED, Broome HE. Monoclonal antibodies in the treatment of hematologic malignancy.  Best Practices and Research Clinical Haematology. 23(3):403-16, 2010

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe L-A, Devine S, Farag S, Hurd D, Ball ED, McCarthy P, Lister J, Shea TC, Linker CReduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood and Marrow Transplant, 17:558-565, 2011.

Zhou J, Bashey A, Zhong R, Corringham  S, Messer K, Pu M, Ma W, Soiffer R, Mitrovich RC, Lowy I, and Ball ED.  CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation is Associated with T cell Activation but not Increased Levels of T Regulatory Cells. Biology of Blood and Marrow Transplantation. 17: 403-16, 2011.

Cortes J, Kantarjian H, Ball ED, DiPersio J, Kolitz J, Fernandez H, Goodman M, Borthakur G, Baer M, Wetzler M.  Phase II Study of p53 Antisense Oligonucleotide (Cenersen) plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myelogenous Leukemia. Cancer Research 15;118(2):418-27, 2012.

Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, and Ball ED. Idiotype Immunization following High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for non-Hodgkin's lymphoma (NHL).  Biol of Blood and Marrow Transplantation, 18(2):257-64, 2012.

Armand P, many others, Ball ED, many others. Classifying Cytogenetics in Patients with AML in complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study. Biol of Blood and Marrow Transplantation, 18(2):280-8, 2012.

Heidary DK, Huang G, Ma J, Boucher D, Davies R, Foster C, Chen G, Zhou JH, Liu M, Namchuck M, Yao M, Stack J, Ball ED, Henkel G.  A novel FLT3 inhibitor increases survival in a FLT3-ITD driven AML mouse model: A comparison with FLT3 inhibitors in clinical trials.  J Medicinal Chemistry, Jan 26;55(2):725-34, 2012.


Ruikun Zhong, M.D., Project Scientist

Jiehua Zhou, M.D., Project Scientist

Larisa Balaian, PhD., Project Scientist